PHARMAESSENTIA CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 285.5 TWD | -1.04% |
|
0.00% | -17.49% |
| Sales 2024 * | 8.39B 258M 21.47B | Sales 2025 * | 12.41B 381M 31.75B | Capitalization | 94.76B 2.91B 243B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.05B 62.96M 5.25B | Net income 2025 * | 4.84B 149M 12.38B | EV / Sales 2024 * | 9.2 x |
| Net cash position 2024 * | 17.55B 539M 44.91B | Net cash position 2025 * | 18.49B 568M 47.32B | EV / Sales 2025 * | 6.15 x |
| P/E ratio 2024 * |
41.6
x | P/E ratio 2025 * |
17.6
x | Employees | 131 |
| Yield 2024 * |
-
| Yield 2025 * |
0.57% | Free-Float | 74.3% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.04% | ||
| Current month | -11.34% | ||
| 1 month | -10.22% | ||
| 3 months | -10.50% | ||
| 6 months | -7.31% | ||
| Current year | -17.49% |
1 week
285.50
300.00
1 month
281.00333.00
Current year
281.00358.00
1 year
274.00392.00
3 years
69.00622.00
5 years
53.60622.00
10 years
45.16622.00
| Managers | Title | Age | Since |
|---|---|---|---|
Kuo Chung Lin
CEO | Chief Executive Officer | - | 01/03/01 |
Hsueh Ling Chang
DFI | Director of Finance/CFO | - | 14/15/14 |
Lih-Ling Lin
CTO | Chief Tech/Sci/R&D Officer | - | 01/22/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Patrick Yang
BRD | Director/Board Member | 75 | 01/14/01 |
Tien Chang
BRD | Director/Board Member | - | 30/06/30 |
Ching Liu Chan
CHM | Chairman | - | 01/03/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.31% | 24 M€ | +6.40% | ||
| 0.12% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 285.5 | -1.04% | 825,666 |
| 25/24/25 | 288.5 | -3.83% | 1,219,130 |
| 24/24/24 | 300 | +4.35% | 1,363,140 |
| 23/24/23 | 287.5 | -0.17% | 899,054 |
| 22/24/22 | 288 | +0.88% | 1,435,876 |
End-of-day quote Taiwan S.E., April 26, 2024
More quotes
PharmaEssentia Corp is a Taiwan-based company mainly engaged in the research, development, production and sale of new drugs. The Company is engaged in the research and development of new drugs, which are used for treatment of hematology, such as meloproliferative neoplasms (MPN), neutropenia, anemia; infectious disease, such as hepatitis C and hepatitis B; dermatology, such as psoriasis, and neurology, such as multiple sclerosis, among others. The Companyâs products include KX01, P1101, Polycythemia Vera (PV), PEG-GCSF, PEG-EPO and others. The Company distributes its products within domestic market and to overseas markets.
Calendar
27/05/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
285.5
TWD
Average target price
417.2
TWD
Spread / Average Target
+46.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.49% | 2.9B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 6446 Stock
